Clinical Trial Search

Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants

Primary: Overall Survival — 8.1; 10.6 months — p=<0.01

Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103

Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10

Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants

Primary: Progression Free Survival (PFS) — 5.88; 5.85 Months — p=0.8072

Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants

Primary: Patient Response — 2; 1; 2; 27 participants

Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 57 percentage of participants

Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy — 10.97; 10.94 months — p=0.3775

Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17

Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants

Primary: Progression-free Survival (PFS) — 14.5; 10.7 months

Primary: Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) — 2.6 percentage of participants

Primary: Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I) — 25 mg/day

Primary: Objective Response Rate (Part I) — 4; 20; 1; 0 Participants

Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) — 5.2; 0; 0 percentage of participants

Primary: Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population — 4.3; 5.2 Months — p=0.0170

Primary: Progression Free Survival (PFS) — 1.9; 1.7 Months

Primary: Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST) — 0.697; 0.576 proportion of participants

Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…

Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 4.8…

Primary: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population — 9.56; 9.17 Months — p=0.3693

Primary: OS — 15.77; 11.10 month — p=<0.001

Primary: Progression-free Survival (PFS) — 4.4; 5.5 Months — p=0.0097

Primary: Percentage of Participants With Grade ≥3 AEs — 49.7 percentage of participants

Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Progression Free Survival Rate — 13 percentage of patients with PFS

Primary: Overall Survival (OS) for the Full Analysis Population (FAP) — 10.2177; 9.6591 months — p=0.0556

Primary: Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS) — 5.55; 5.36 months — p=0.3504